Zambon Announces European Commission Approval of Hopledo for Parkinson’s Disease Motor Fluctuations
Milan, Italy – August 28, 2026 Zambon announced that the European Commission has granted marketing authorization for Hopledo® (modified-release...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Milan, Italy – August 28, 2026 Zambon announced that the European Commission has granted marketing authorization for Hopledo® (modified-release...
BRESSO, Milan, Italy, June 29, 2026 Zambon has announced that the Committee for Medicinal Products for Human Use (CHMP)...
BRIDGEWATER, N.J., June 5, 2026 Amneal Pharmaceuticals announced positive interim results from the ongoing Phase 4 ELEVATE-PD study, demonstrating...
